Revenue segments as reported by the company.

Premiums

Services

Investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefits

Operating costs

Depreciation and amortization

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Humana

Humana Inc. engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental plans such as Medicare, and State-based contracts. The Group and Specialty segment contains employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, military services and other supplemental health & voluntary insurance. The Healthcare Services segment offers services such as pharmacy solutions, provider services, clinical care, predictive modeling and informatics to other Humana businesses, as well as external health plan members, and other employers. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Humana exceeds earnings expectations, focuses on value-based care growth

Humana's strong financial performance and growth in value-based care position the company well for future success. Addressing audit error rates, uncertainties around RADV, and managing costs are key challenges. Opportunities in recruiting, revenue growth, and strategic partnerships offer avenues for further growth.

Humana exceeds Q1 expectations, eyes industry growth amidst challenges

Humana's strong Q1 performance and strategic decisions position it well for growth
Challenges like rate disruptions and Medicaid redeterminations require close monitoring
Opportunities in industry growth, member engagement, and benefit enhancements ahead
Commitment to long-term goals and high-quality service evident in company's outlook

Humana meets Q2 expectations, eyes growth in MA platform

Humana's Q2 performance met expectations with a focus on MA platform growth and disciplined investments.
Challenges include higher utilization in Medicare Advantage and broad-based medical cost trends.
Strategic benefits adjustments and competitive positioning present opportunities for growth and margin expansion.
Expectations for 2024 include maintaining market share, offsetting costs, and achieving strong membership growth.

Humana surpasses Q3 earnings expectations, eyes $37 EPS target

Humana's Q3 performance exceeded expectations, with strong membership growth and strategic initiatives driving future profitability.
While facing challenges in benefit ratios and regulatory changes, Humana remains focused on achieving long-term financial targets.
The company's commitment to operational excellence, membership growth, and pricing actions positions it for sustained success.
Strategic partnerships and risk management efforts showcase Humana's resilience and adaptability in a dynamic healthcare landscape.

Humana faces challenges from rising costs but eyes long-term growth

Humana's Q4 2023 earnings call highlighted challenges from increased medical costs and utilization trends impacting financial performance and outlook.
Despite disappointments in short-term results, the company remains confident in the long-term attractiveness of the Medicare Advantage sector.
Strategic efforts to restore margins, address utilization drivers, and engage with providers reflect a proactive approach to managing industry dynamics.
Balancing profitability with membership growth through benefit adjustments and pricing actions is crucial for Humana's sustainable financial performance.

Humana reports solid Q1 performance, eyes margin recovery in 2025

Humana's Q1 2024 earnings call highlighted a strong start to the year, challenges in the industry for 2025, and a focus on margin recovery and growth opportunities. The company remains confident in its outlook, emphasizing pricing discipline and maintaining a strong value proposition in the market.

Humana surpasses Q2 expectations, addresses cost pressures for growth

Humana's Q2 2024 performance exceeded expectations, driven by strong Medicare business and growth in Medicaid and primary care segments.
Challenges such as medical cost pressures were addressed through mitigation measures, while opportunities lie in strategic initiatives and long-term planning.
The company's focus on value, disciplined cost management, and operational efficiency position it well for sustained growth and value creation.

Humana surpasses Q3 expectations, eyes growth through efficiency and investments

Humana's Q3 performance exceeded expectations, with a focus on balancing earnings and investments. The company is strategically positioned to drive growth through membership expansion and operational efficiency. Challenges include managing costs and understanding market dynamics, with opportunities in improving Stars ratings and expanding senior care services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Humana Inc. ("Humana Inc.") (NYSE:HUM) concerning possible violations of federal securities laws. Humana is the subject of a Bloomberg article published on October 2, 2024, titled: "Humana Plunges as Insurer Falters on Medicare Star Ratings.

Humana Inc. Being Investigated on Behalf of Humana Inc. Investors. Contact Levi & Korsinsky For Details.

LOS ANGELES, CA / ACCESSWIRE / October 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Encouraged To Help The Schall Law Firm Look Into Whether Humana Inc. Committed Securities Fraud

Humana (HUM) shares slid after Jefferies downgraded the insurer's stock, pointing to the negative impacts of the company's latest ratings for its Medicare offerings.

Humana Stock Is at Multiyear Lows as Investors Digest Its Medicare Rating

HUM is facing significant challenges, including membership decline, rising costs and debt burden.

Humana Stock Getting Closer to 52-Week Lows: A Buying Opportunity?

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Humana Inc. (“Humana” or the “Company”) (NYSE: HUM) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Humana investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Humana Inc. (HUM) on Behalf of Investors

Occidental Petroleum

October 7, 2024 (Maple Hill Syndicate) –- “I can only buy on train wrecks,” famed money manager John Neffonce said.

Occidental and Humana Are on the Casualty List

LOS ANGELES, CA / ACCESSWIRE / October 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Humana Inc Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Impacted Shareholders To Help

LOS ANGELES, CA / ACCESSWIRE / October 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Encouraged To Join The Schall Law Firm's Inquiry Into Humana Inc. For Possible Securities Fraud

LOS ANGELES, CA / ACCESSWIRE / October 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Humana Inc Is Being Looked Into For Violating Securities Laws And The Schall Law Firm Urges Affected Shareholders To Reach Out

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Humana Inc. (“Humana” or the “Company”) (NYSE: HUM) investors concerning the Company's possible violations of federal securities laws. On October 2, 2024, Humana disclosed that it has “approximately 1.6 million, or 25%, of its members currently enrolled in plans rated 4 stars and above for 2025, a reduction from 94% in 2024.” On this news, Humana's stock price fell $32.98, or 11.8%, to close a.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Humana Inc. (HUM) on Behalf of Investors

Humana Inc.'s stock was up 2% Friday after three straight sessions of declines, but investors paying attention to the performance of its bonds on Thursday may have had something of a heads-up on the stock's recovery.

Humana's stock ends a three-day selloff, but investors watching its bonds may have had a heads-up

LOS ANGELES, CA / ACCESSWIRE / October 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Invited To Join The Schall Law Firm In An Investigation Into Humana Inc. For Possible Securities Fraud

SAN DIEGO , Oct. 3, 2024 /PRNewswire/ -- The Shareholders Foundation, Inc. announces that a lawsuit was filed by a NYSE: HUM investor against certain directors of Humana Inc. Investors who purchased shares of Humana Inc. (NYSE: HUM) prior to August 2022 and continue to hold any of those NYSE: HUM shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. In June 2024 an investor in NYSE: HUM shares filed a lawsuit over alleged securities laws violations by Humana Inc. The plaintiff alleged that the defendants continued to assure investors—and analysts who repeatedly inquired about potential pent-up demand for healthcare services that built-up under COVID restrictions—that "in-patient unit costs and non-in-patient trends [were] coming in lower than [the Company] initially estimated" and that" there really isn't pent-up demand that [the Company has] to be concerned about" negatively impacting utilization rates and profitability, and that Humana made several additional disclosures about its profitability and financial condition, however, Defendants continued to downplay pressures on the Company's adjusted EPS resulting from increased medical costs associated with pent-up demand for healthcare procedures (especially as COVID concerns abated) which, contrary to the Company's assurances, resulted in increased utilization rates and costs.

NYSE: HUM Lawsuit against Directors filed - Investors in shares of Humana Inc. (NYSE: HUM) should contact the Shareholders Foundation

The health insurer has lost 24% in the week to data after it said the government is set to cut the rating on a large Medicare Advantage plan.

Humana's stock extends losses as BofA downgrades to sell on concerns about margin recovery

SAN DIEGO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Humana Inc. (NYSE: HUM) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

Johnson Fistel Begins Investigation into Humana, Inc. Following a Significant Drop in the Company's Stock

Shares in Humana (HUM) will likely remain on watchlists after plummeting Wednesday to levels not seen in more than four years after the Centers for Medicare and Medicaid Services (CMS) downgraded a large portion of the health insurer's Medicare offerings.

Watch These Humana Price Levels as Stock Plummets on Medicare Plan Ratings Downgrade

Investors can contact the law firm at no cost to learn more about recovering their losses

Humana Inc. Investors: Company Investigated by the Portnoy Law Firm

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Humana Inc. (“Humana” or the “Company”) (NYSE: HUM) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On October 2, 2024, Humana disclosed that it has “approximately 1.6 million, or 25%, of its members currently enrolled in plans rated 4 stars and above for 2025, a reduction from 94% in.

The Law Offices of Frank R. Cruz Announces Investigation of Humana Inc. (HUM) on Behalf of Investors

After wavering for much of the session, major U.S. equities indexes closed out the second trading day of the fourth quarter with minimal gains as investors weighted the implications of a strike by port workers and escalating geopolitical tensions.

S&P 500 Gains and Losses Today: Humana Stock Falls as Medicare Plan Ratings Drop

LOS ANGELES, CA / ACCESSWIRE / October 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Humana Inc Is Being Looked Into By The Schall Law Firm For Securities Law Violations And Affected Shareholders Should Reach Out

Lamb Weston Hlds

NIKE

A private reading on payrolls had markets rethinking rate-cut bets just days ahead of the monthly jobs report.

Stock Market Today: Stocks Waver on Resilient Employment Data

The best traders don't play offense. They play defense.

Stock Of The Day: Will Humana Remember?

Shares of health insurance provider Humana (HUM) plunged to their lowest level since 2020 after a large share of its Medicare offerings were downgraded by the Centers for Medicare and Medicaid Services (CMS).

Humana Stock Plunges as Insurer's Medicare Plan Ratings Plummet

LOS ANGELES--(BUSINESS WIRE)--HUM Investors Have Opportunity to Join Humana Inc. Fraud Investigation with the Schall Law Firm.

HUM Investors Have Opportunity to Join Humana Inc. Fraud Investigation with the Schall Law Firm

Shares of Humana Inc (HUM, Financial) fell 17.63% in mid-day trading on Oct 2. The stock reached an intraday low of $213.31, before recovering slightly to $230.18, down from its previous close of $279.45.

News for Humana Stock (HUM)